Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Ramucirumab |
| Synonyms | |
| Therapy Description |
Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ramucirumab | Cyramza | LY3009806 | VEGFR2 Antibody 4 | Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02597036 | Phase I | LY3127804 Ramucirumab | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
| NCT02711553 | Phase II | Ramucirumab Merestinib Cisplatin + Gemcitabine | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | FRA | ESP | DEU | BEL | AUT | 13 |
| NCT02443883 | Phase II | Ramucirumab | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | Completed | USA | FRA | 10 |
| NCT02581215 | Phase II | Ramucirumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
| NCT02314117 | Phase III | Capecitabine Fluorouracil Cisplatin Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 13 |
| NCT02079636 | Phase I | LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab | A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | Completed | USA | ESP | 0 |
| NCT02514551 | Phase II | Paclitaxel Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | Completed | USA | ITA | ESP | DEU | CAN | BEL | 5 |
| NCT02435433 | Phase III | Ramucirumab | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
| NCT02564198 | Phase I | Ramucirumab | A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors | Completed | USA | 0 |
| NCT03904108 | Phase II | Ramucirumab | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | Recruiting | USA | 0 |
| NCT02426125 | Phase III | Ramucirumab Docetaxel | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 16 |
| NCT03760822 | Phase II | Paclitaxel + Ramucirumab Ramucirumab | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE) | Recruiting | FRA | 0 |
| NCT02520141 | Phase II | Ramucirumab | Ramucirumab for Advanced Pre-treated Biliary Cancers | Active, not recruiting | USA | 0 |
| NCT04557384 | Phase I | Ramucirumab | A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer | Terminated | USA | 1 |
| NCT02065765 | Phase II | Ramucirumab | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | No longer available | DEU | AUT | 3 |
CKB BOOST